SCHEMBL5408837

SCHEMBL5408837

NC(=O)c1ccc(C(F)(F)F)cc1C(F)(F)F.O=S(=O)(O)/C=C/c1cccc(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 1/20 0.44
FLT4 P35916 1/20 0.44
KDR P35968 1/20 0.44
CES2 O00748 1/20 0.43
CYP1A2 P05177 2/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PLA2G1B P04054 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ATG4B Q9Y4P1 1/20 0.40
CYP2C9 P11712 1/20 0.39
GPR52 Q9Y2T5 1/20 0.39
NFE2L2 Q16236 1/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27717776 0.89 PTGES2 (0.46) CYP1A2MEN1NPC1CYP3A4CYP2C19
SCHEMBL5408888 0.89 PTGES2 (0.46) CYP1A2MEN1NPC1CYP3A4CYP2C19
SCHEMBL5403847 0.89 KDR (0.51) FLT1FLT4KDRCES2CYP1A2
SCHEMBL5407610 0.89 CES2 (0.47) FLT1FLT4KDRCES2MEN1
SCHEMBL5411908 0.85 MAOB (0.43) CES2GPR52NFE2L2
SCHEMBL5411196 0.85 GRIK1 (0.40) FLT1FLT4KDRCYP1A2MEN1
SCHEMBL27717857 0.85 GRIK1 (0.40) FLT1FLT4KDRCYP1A2MEN1
SCHEMBL4261210 0.83 NAMPT (0.45) CES2NFE2L2
SCHEMBL5409657 0.83 CES2 (0.43) FLT1FLT4KDRCES2CYP1A2
SCHEMBL5408840 0.82 FLT1 (0.56) FLT1FLT4KDRCES2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US claimed
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270874-A1 Styrylsulfonamides STS, SULT1E1, BRCA1 FLT1 4126/4885FLT4 4438/4885KDR 4332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.